TaiMed BiologicsROCO:4147 55 Days Payable is 36.54 as of Dec. 2025, which is 43% below its 10-year median of 64.60. GuruFocus rates ROCO:4147 with a GF Score™ of 55/100 and a GF Value™ of NT$85.90 (Modestly Undervalued). Among 701 Biotechnology companies, TaiMed Biologics ranks worse than 88.73% on this metric.
The historical rank and industry rank for TaiMed Biologics's Days Payable or its related term are showing as below:
ROCO:4147'
s Days Payable Range Over the Past 10 Years
Min: 6.52 Med: 64.6 Max: 209.66
Current: 19.79
During the past 13 years, TaiMed Biologics's highest Days Payable was 209.66. The lowest was 6.52. And the median was 64.60.
ROCO:4147's Days Payable is ranked worse than 88.73% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs ROCO:4147: 19.79
TaiMed Biologics's Days Payable
declined
from Dec. 2024 (189.68) to Dec. 2025 (36.54).
It may suggest that TaiMed Biologicsaccelerated paying its suppliers.
TaiMed Biologics Days Payable Related Terms
TaiMed Biologics Days Payable Historical Data
* Premium members only.
The historical data trend for TaiMed Biologics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4147 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, TaiMed Biologics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiMed Biologics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiMed Biologics's Days Payable distribution charts can be found below:
* The bar in red indicates where TaiMed Biologics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
TaiMed Biologics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TaiMed Biologics (ROCO:4147) has a Days Payable of 36.54 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on TaiMed Biologics and its competitors. This is 43% below median its historical median of 64.60. Over the past decade, TaiMed Biologics' Days Payable has ranged from 6.52 to 209.66. According to the industry distribution chart, TaiMed Biologics ranks #622 out of 701 companies in the Biotechnology industry, placing it in the top 88.7%.
Is TaiMed Biologics' Days Payable too high?
TaiMed Biologics' current Days Payable of 36.54 is 43% below median its 10-year median of 64.60. Over the past 10 years, this metric has ranged from a low of 6.52 to a high of 209.66. The Biotechnology industry median Days Payable is 112.84. TaiMed Biologics' value of 36.54 is 67.6% below this industry median. Based on the distribution chart, TaiMed Biologics ranks #622 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TaiMed Biologics has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiMed Biologics ranks #622 out of 701 companies for Days Payable. This places TaiMed Biologics in the lower half of its industry. The industry median Days Payable is 112.84. TaiMed Biologics' value of 36.54 is 67.6% below this benchmark. Historically, TaiMed Biologics' own Days Payable has ranged from 6.52 to 209.66 over the past decade. While the company's 10-year median is 64.60 vs. the industry median of 112.84, TaiMed Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TaiMed Biologics's current Days Payable of 36.54 is 67.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on TaiMed Biologics and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TaiMed Biologics's current Days Payable is 36.54, which is 43% below median its own 10-year median of 64.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$85.90, compared to a current price of NT$69.50 — trading 19.1% below its estimated fair value. The current Days Payable is 36.54, which is 43% below median its 10-year median of 64.60 and 67.6% below the Biotechnology industry median of 112.84. TaiMed Biologics' overall GF Score™ is 55/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current Days Payable is 36.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?
Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued.
The current stock price of NT$69.50 is trading 19.1% below its estimated GF Value™ of NT$85.90.
GuruFocus considers TaiMed Biologics to be Modestly Undervalued.
Key valuation signals for ROCO:4147:
Days Payable: 36.54 (43% below median its 10-year median of 64.60)
GF Value™: NT$85.90 vs. price of NT$69.50 (19.1% below fair value)
Industry Position: 67.6% below the Biotechnology median (#622 of 701)
No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
55GF Score
Get the complete analysis for ROCO:4147
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4147 has been successfully added to your 
